Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rockwell MedicalFRA:RWM 55 Equity-to-Asset is 0.62 as of Jun. 2026, which is 38% above its 10-year median of 0.45. GuruFocus rates FRA:RWM with a GF Score™ of 55/100 and a GF Value™ of €5.73 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Rockwell Medical ranks better than 52.84% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Rockwell Medical's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €30.45 Mil. Rockwell Medical's Total Assets for the quarter that ended in Jun. 2026 was €49.07 Mil.
Therefore, Rockwell Medical's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.62.
The historical rank and industry rank for Rockwell Medical's Equity-to-Asset or its related term are showing as below:
FRA:RWM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13 Med: 0.45 Max: 0.67
Current: 0.62
During the past 13 years, the highest Equity to Asset Ratio of Rockwell Medical was 0.67. The lowest was -0.13. And the median was 0.45.
FRA:RWM's Equity-to-Asset is ranked better than 52.84% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs FRA:RWM: 0.62
Rockwell Medical (FRA:RWM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Rockwell Medical Equity-to-Asset Related Terms
Rockwell Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RWM vs BTAI, MRMD, TXMD: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Rockwell Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (FRA:RWM) has a Equity-to-Asset of 0.62 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rockwell Medical and its competitors. This is 38% above median its historical median of 0.45. According to the industry distribution chart, Rockwell Medical ranks #474 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 47.2%.
Is Rockwell Medical's Equity-to-Asset too high?
Rockwell Medical's current Equity-to-Asset of 0.62 is 38% above median its 10-year median of 0.45. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Rockwell Medical's value of 0.62 is 1.6% above this industry median. Based on the distribution chart, Rockwell Medical ranks #474 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rockwell Medical has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Equity-to-Asset compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #474 out of 1005 companies for Equity-to-Asset. This puts Rockwell Medical in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Rockwell Medical's value of 0.62 is 1.6% above this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 0.61, Rockwell Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current Equity-to-Asset of 0.62 is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Equity-to-Asset is 0.62, which is 38% above median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Fairly Valued. The stock's GF Value™ is €5.73, compared to a current price of €5.25 — trading 8.4% below its estimated fair value. The current Equity-to-Asset is 0.62, which is 38% above median its 10-year median of 0.45 and 1.6% above the Drug Manufacturers industry median of 0.61. Rockwell Medical's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current Equity-to-Asset is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €5.25 is trading 8.4% below its estimated GF Value™ of €5.73.
GuruFocus considers Rockwell Medical to be Fairly Valued.
Key valuation signals for FRA:RWM:
Equity-to-Asset: 0.62 (38% above median its 10-year median of 0.45)
GF Value™: €5.73 vs. price of €5.25 (8.4% below fair value)
Industry Position: 1.6% above the Drug Manufacturers median (#474 of 1005)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
55GF Score
Get the complete analysis for FRA:RWM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 
